Egletin tartrate, a new type 1 diabetes drug of LVYE pharmaceutical, has obtained clinical approval

LVYE Pharmaceutical (02186 HK) announced that the group's products under research, which are expected to be approved as class 1.1 new chemical drugs, egletin tartrate tablets have been approved by the State Food and Drug Administration (CFDA) in the first phase of clinical trials The company expects that egletin tartrate tablets will be approved for the treatment of type II diabetes Egletin tartrate tablets are dipeptidyl peptidase IV inhibitory tablets It is expected that egletin tartrate tablets will be approved for the treatment of type II diabetes The group holds the exclusive intellectual property license issued by East Asia Pharmaceutical Co., Ltd to develop and commercialize egletin tartrate tablets in China, including the exclusive right to develop egletin tartrate tablets in the name of the group for production and sale The new drug certificate and approval number issued by SFDA will apply for registration in the name of the group and be approved According to the statistics of IMS Health incorporated, the market value of China's diabetes treatment products in 2013 was about 7.8 billion yuan, with a compound annual growth rate of 23.4% from 2011 to 2013.